Skip Navigation


JAC Advance Access originally published online on February 13, 2008
Journal of Antimicrobial Chemotherapy 2008 61(5):1120-1124; doi:10.1093/jac/dkn046
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/5/1120    most recent
dkn046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Palit, P.
Right arrow Articles by Ali, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palit, P.
Right arrow Articles by Ali, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani

Partha Palit and Nahid Ali*

Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, India

Received 29 June 2007; returned 18 November 2007; revised 17 December 2007; accepted 20 January 2008

* Corresponding author. Tel: +91-33-2473-3491, 91-33-2473-3493/0492; Fax: +91-33-2473-5197/0284; E-mail: nali{at}iicb.res.in

Objectives: This study was executed to investigate the efficacy of oral therapy and preliminary leishmanicidal mechanism of sertraline, a selective serotonin reuptake inhibitor widely used for the management of depression, against Leishmania donovani, a causative agent of visceral leishmaniasis (VL).

Methods: The effect of the drug was determined for: (i) direct promastigote killing by inhibition of MTT reduction and (ii) killing activity against intracellular amastigotes in mouse peritoneal macrophages by microscopic evaluation of surviving amastigotes in macrophages in Giemsa-stained slides. Furthermore, the oral therapy of sertraline against established VL in BALB/c mice was evaluated through estimation of splenic and liver parasite burdens by Leishman Donovan units. Moreover, the preliminary mechanism of action of the drug against promastigotes was assessed by measuring the intracellular ATP levels and oxygen consumption of treated cells.

Results: Sertraline killed L. donovani promastigotes and intracellular amastigotes with 50% inhibitory concentrations (IC50s) of 2.2 and 2.3 mg/L, respectively. The drug was also effective in eliminating splenic (72%) and liver (70%) parasite loads in infected BALB/c mice through oral therapy. A sertraline-induced fall in cytoplasmic ATP levels and oxygen consumption rate in promastigotes suggests the involvement of an apoptosis mode of cell death in the treated parasites.

Conclusions: Sertraline could be a promising pharmacological tool for the oral treatment of VL.

Keywords: antileishmanial chemotherapy , BALB/c mice , ATP , oxygen consumption


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.